Immunovant, Inc (NASDAQ:IMVT) Posts Durable Graves’ Remission, Strengthens Near-Term Development Momentum
Immunovant shows clinical durability in Graves’ disease data while corporate moves sharpen program execution and maintain a cash-rich balance sheet. Technical indicators suggest a constructive near-term setup that aligns with a valuation WMDST classifies as under-valued.







